Abstract 1218P
Background
Immunotherapy has been introduced as adjuvant treatment and more recently in clinical trials investigating the perioperative setting in patients with early-stage non-small cell lung cancer (NSCLC). The retrospective FALCONS study aims to enhance understanding of early-stage NSCLC patients' characteristics and care pathways by complementing clinical trial evidence with real-world insights. FALCONS is based on the French national registry EPITHOR, which collects epidemiological and clinical data on thoracic surgical procedures.
Methods
FALCONS is analyzing data from patients who underwent thoracic surgery from 2016 to 2018 (Cohort A, N=9429, 27 sites), including recipients of neoadjuvant treatment (Cohort A1, n=758) and adjuvant treatment (Cohort A2, n=993). Baseline characteristics, treatment management and overall survival (OS) were analyzed in each cohort over a minimum 5-year period. A forthcoming chart review will complete the analysis (Cohort B, N=517, 11 sites).
Results
An even distribution of male/female patients and smoking habits was observed in all cohorts. Cohort A1 and A2 patients were younger than A patients. In the neoadjuvant A1 cohort, there were fewer ECOG PS 0 patients (A1, 42%; A2, 53%; A, 49%), more dyspnea score 0 (A1, 63%; A2, 59%; A, 58%), more squamous histology (A1, 31%; A2, 26%; A, 24%), more pneumonectomy surgeries (A1, 16%; A2, 11%; A, 6%) and fewer comorbidities (A1, 86%; A2, 92%; A, 90%). Stage III–IV TNM pre-surgery was more frequent in A1 (67%; A2, 32%; A, 19%) compared to post-surgery (A1, 46%; A2, 48%; A, 24%). As of 31 December 2023, the estimated 5-year OS rates were 53% in A1, 52% in A2 and 65% in A. Median OS were 65.6 (95% CI 58.2–77.6), 64.8 (95% CI 58.9–70.6) months and not reached, respectively.
Conclusions
This study confirms in a real world setting a recent meaningful improvement in survival outcomes, probably reflecting the progressive implementation in France of the regulatory requirement for multidisciplinary treatment decisions of NSCLC. Despite these encouraging results, the morbi-mortality remains high in early stages highlighting the need for new treatments for NSCLC at operable stages.
Clinical trial identification
Editorial acknowledgement
Medical writing assistance was provided by Isabelle Lawrence, Potentiel d’Action (France).
Legal entity responsible for the study
Roche.
Funding
Roche.
Disclosure
M. Wislez, M. Alifano, H. Lena: Financial Interests, Advisory Board: Roche. S. Michiels: Financial Interests, Personal, Other, DSMB member: Servier, Biophytis, Yuhan, IQVIA, Kedrion; Financial Interests, Personal, Advisory Board, Study Scientific Committee member: Roche. L. Emonnot, C. Esnault, S. Gally, L. Goncalves, C. Kuypers, V. Machuron, S. Micon, S. Saget, K. Thokagevistk: Other, Full or part-time Employment: Roche. L. Boyer: Financial Interests, Institutional, Advisory Role: Roche. P.A. Thomas: Non-Financial Interests, Institutional, Project Lead, Co-gestionnaire EPITHOR: CNP-CTCV; Financial Interests, Institutional, Trial Chair: Roche SA; Financial Interests, Institutional, Expert Testimony: Ethicon; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1074TiP - A phase I study of GIGA-564, a minimally blocking anti-CTLA-4 monoclonal antibody
Presenter: James Gulley
Session: Poster session 04
1075TiP - A phase I trial of ATG-101, an investigational PD-L1×4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN
Presenter: Junli Xue
Session: Poster session 04
Resources:
Abstract
1083P - KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Presenter: Reinhard Dummer
Session: Poster session 04
1084P - Phase II study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
Presenter: Muhammad Khattak
Session: Poster session 04
1085P - Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial
Presenter: Brigit van Dijk
Session: Poster session 04
1086P - Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial
Presenter: Manon Vounckx
Session: Poster session 04
1087P - Phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations
Presenter: Kevin Kim
Session: Poster session 04
1088P - Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study
Presenter: Andrea Boutros
Session: Poster session 04
1089P - Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
Presenter: Elizabeth Burton
Session: Poster session 04
Resources:
Abstract
1090P - High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma
Presenter: Lotte Hoeijmakers
Session: Poster session 04